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Global cancer mortalityAbstract Background: Cancer continues to rise as a contributor to premature
death in the developing world. Despite this, little is known about whether cancer
outcomes are related to a countrys income level, and what aspects of national
healthcare systems are associated with improved cancer outcomes.
Methods: The most recent estimates of cancer incidence and mortality were used
to calculate mortality-to-incidence ratio (MIR) for the 85 countries with reliable
data. Countries were categorized according to high-income (Gross Domestic Product
(GDP) > $15,000) or middle/low-income (GDP < $15,000), and a multivariate linear
regression model was used to determine the association between healthcare system
indicators and cancer MIR. Indicators study included per capita GDP, overall total
healthcare expenditure (THE), THE as a proportion of GDP, total external beam
radiotherapy devices (TEBD) per capita, physician density, and the year 2000 WHO
healthcare system rankings.
Results: Cancer MIR in high-income countries (0.47) was significantly lower than
that of middle/low-income countries (0.64), with a p < 0.001. In high-income coun-
tries, GDP, health expenditure and TEBD showed significant inverse correlations
with overall cancer MIR. A $3040 increase in GDP (p = 0.004), a $379 increase in
116 A. Batouli et al.THE (p < 0.001), or an increase of 0.59 TEBD per 100,000 population (p = 0.027) were
all associated with a 0.01 decrease in cancer MIR. In middle/low-income countries,
only WHO scores correlated with decreased cancer MIR (p = 0.022); 12 specific can-
cer types also showed similar significant correlations (p < 0.05) as overall cancer
MIR.
Conclusions: The analysis of this study suggested that cancer MIR is greater in
middle/low-income countries. Furthermore, the WHO healthcare score was associ-
ated with improved cancer outcomes in middle/low-income countries while abso-
lute levels of financial resources and infrastructure played a more important role
in high-income countries.
ª 2013 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Background
Cancer is an increasingly important problem in the
developing world. Greater than half of cancer cases
worldwide arise in developing countries, and this
proportion is expected to rise to 70% by 2020 [1].
As cancer incidence and mortality rates remain high
in the developed world and continue to rise in the
developing world [2], the United Nations and WHO
have placed greater emphasis on cancer treatment
and prevention. Despite this emphasis, certain ba-
sic facts about cancer worldwide remain unknown.
Given the cultural, socioeconomic, and environ-
mental factors that can influence cancer outcomes,
it is unclear whether and to what extent national
economic and health system characteristics are
associated with cancer outcomes, and whether a
countrys wealth mediates these effects.
Prior studies have suggested a relationship be-
tween healthcare spending and improved cancer
outcomes in particular subsets of developed coun-
tries [3,4], but these analyses were limited either
by using only one measure of healthcare infrastruc-
ture [3] or by investigating a limited number of
wealthy countries without comparing results to
the less-developed countries [4]. Furthermore,
cancer outcomes may be affected differently in
countries of differing income levels due to the spe-
cific aspects of healthcare infrastructure toward
which spending is geared. Although mortality rates
can illustrate health disparities, they can be mis-
leading due to survival rates and incidences that
may vary substantially among studied groups.
The mortality-to-incidence ratio (MIR) is a useful
tool when comparing diverse groups as it reduces
outcome differences influenced by incidence and
instead approximates a prognosis. This can be help-
ful in identifying underlying causes for differences
in cancer outcomes such as health system-related
attributes [5,6].
One relatively unexplored measure of health-
care infrastructure with a potentially large impacton a nations cancer mortality is access to radiation
therapy [7]. Radiation therapy is often underuti-
lized in developing countries due to the large up-
front cost of capital. In fact, 22 countries in Africa
and Asia lack radiation therapy facilities, while
many others have a fraction of the machines re-
quired by their populations [8]. Furthermore, radi-
ation therapy may be used differently in the
developing world than in countries with high in-
come. In high-income countries, radiation therapy
has been compared with an ‘‘arms race’’ of ever
more expensive and complicated technology of
increasing cost [9]. However, in middle- and
low-income countries, radiation treatment is likely
simpler and may be more focused on palliative
treatment [7]. Whether radiation therapy impacts
cancer MIR in the context of a nations income
and other health infrastructure is unknown. Addi-
tionally, access to radiation therapy is often an
indirect marker of the availability of multidisciplin-
ary cancer centers and overall access to cancer
care. Thus, measurement of access to radiotherapy
perhaps provides one of the most specific measur-
able indicators of access to cancer treatment
worldwide.
The overall organization of a national healthcare
system is another factor that may affect cancer
MIR. The year 2000 World Health Organization
(WHO) overall healthcare system rankings provided
a systematically derived, quantifiable measure of
healthcare system fairness and effectiveness for
191 countries [10,18]. The ranking was based on
healthcare system responsiveness, the distribution
of responsiveness, overall level and distribution of
health, and the fairness of distribution of the finan-
cial burden of a system. No study to date has mea-
sured the association between these rankings and
cancer MIR. See Appendix A for a more detailed
explanation of the WHO scores.
This study foremost investigated the extent to
which cancer MIR varies between middle/low-in-
come and high-income countries. Secondly, the
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outcomes and healthcare system factors, including
access to radiation therapy and WHO ranking in
both middle/low-income and high-income coun-
tries. It was hypothesized that cancer MIR is higher
in middle/low-income countries. Furthermore, due
to the vast disparities in resources, healthcare sys-
tems and disease burdens in the developed vs.
developing world, it is also hypothesized that fac-
tors affecting outcomes in middle/low-income
countries would differ from those in high-income
countries.
2. Methods
2.1. Outcome variable
Age standardized cancer incidence and death rates
were obtained from the International Agency for
Research on Cancers GLOBOCAN 2008 database,
which included the most recent data from each
country worldwide [27]; 26 specific cancer types
were studied including bladder, central nervous
system (CNS), colorectal, gallbladder, Hodgkins
lymphoma, kidney, larynx, leukemia, lip and oral
cavity, liver, lung, melanoma of the skin, multiple
myeloma, nasopharynx, non-Hodgkins lymphoma,
esophagus, other pharynx, pancreas, stomach, thy-
roid, prostate, testis, breast, cervical, uterine, and
ovarian. While incidence data were available for a
majority of countries, only 85 countries had recent
(post-2005) non-estimated mortality data and were
thus included for analysis. Of these 85 countries, 41
were in Europe, 24 in the Americas, 17 in Asia, 2 in
Oceania and only 1 in Africa. While a very broad
range of countries from all continents were in-
cluded, the nations with the very lowest incomes,
including those with GDPs of less than $1690, were
excluded due to lack of data. Using these recent
estimates of cancer incidence and mortality, MIR
was calculated for the 85 countries with reliable
data.
2.2. Independent variables
Three categories of variables with cancer MIR were
correlated: overall monetary resources, healthcare
system infrastructure, and healthcare system orga-
nization. Per capita gross domestic product (GDP)
[20] and per capita total health expenditure
(THE) [20] were used as measures of overall mone-
tary resources. Physician density [19] and access to
radiation therapy measured by per capita total
external beam devices (TEBD) [21] were used as
measures of healthcare system infrastructure.
Finally, the WHO healthcare system rankings [18]were used as an index of healthcare system organi-
zation and effectiveness. In order to be used in the
linear regression model, the calculated score on
which these rankings were based was used rather
than the rank itself. This score was a continuous
number ranging from 0 to 1. HIV rate, percent of
population that was rural, per capita ethanol con-
sumption, smoking rates and obesity rates were
used as control variables that were consistent in
all statistical models [22–26]. See Table 1 for a
description of each independent variable.
2.3. Statistical method
Multivariate regression modeling was performed
using STATA version IC10 (College Station, TX) with
the dependent variable being age standardized
cancer MIR. Linear regression modeling was used
to analyze the association between variables and
cancer MIR. Normality of distribution was verified
using the Shapiro–Francia test. Each model ad-
justed for the behavioral, demographic and envi-
ronmental risk factors are listed in Table 1. Since
GDP, THE, and TEBD were collinear variables (Pear-
son correlation coefficient >0.7 or <0.7), they
were not simultaneously included in any model.
However, physician density was included in all
models as a control, as it was not collinear with
the other variables. Gross National Income (GNI)
[20] was used as a substitute for GDP in a repeat
analysis to confirm that the two variables acted
similarly.
It was hypothesized that the relationship be-
tween healthcare system indicators and MIR would
be different in lower- vs. higher-income countries,
thus the 85 countries were split at the median GDP
($15,000) and the analysis was stratified by these
two groups. Although there is a continuum of
low-, middle-, and high-income countries as de-
fined by the World Bank, the countries studied
were divided into two equal groups to allow for
adequate sample size in each group for significant
differences and correlations to be noted. This deci-
sion was made a priori to divide countries with
available data into two groups. It is important to
note that the vast majority of the countries with
reliable data that fell in the low/middle-income
group were categorized as upper middle-income
or lower middle-income by the World Bank with
only two countries, Tajikistan and Kyrgyzstan,
being categorized as truly low income.
While this paper focuses on overall cancer MIR,
the above analyses were also performed for each
individual cancer. This step was conducted to ob-
serve if individual cancers would follow the same
trend as overall cancer, thus ensuring that any
Table 1 Variables used in regression model.
Source Description
Independent Variable
WHO healthcare
system score
WHO world health
report 2000 [18]
The score was based on a systems
responsiveness to patients, the fairness
of financial distribution, the overall national
level of health, and the distribution of
health
Physician density WHO global atlas of the
health workforce 2008 [19]
Estimated number of physicians per
100,000 population
Gross domestic product (GDP) World development indicators
database, world bank (2007) [20]
Estimated purchasing parity gross
domestic product per capita in US$
Total health expenditure (THE) World development indicators
database, world bank (2007) [20]
Estimated total (government and private)
health expenditure per capita in US$
Radiation therapy International atomic energy
agencys directory for radiotherapy
2010 [21]
Total external beam radiotherapy
devices per capita (TEBD)
Control Variable
HIV rate CIA world factbook 2008 [22] Estimated percent of population
infected by HIV
Rural population UN world urbanization prospects
(2007) [23]
Estimated percent of population that
live in rural area
Ethanol consumption WHO global alcohol report
(2011) [24]
Estimated per capita liters of ethanol
consumed
Male smoking rate WHO report on the global tobacco
epidemic 2008 [25]
Estimated percent of men who smoke
tobacco regularly
Female smoking rate WHO report on the global tobacco
epidemic 2008 [25]
Estimated percent of women who smoke
tobacco regularly
Male obesity rate WHO global database on bmi
(2008) [26]
Estimated percent of men who have a
BMI > 30
Female obesity rate WHO global database on bmi
(2008) [26]
Estimated percent of women who have
a BMI > 30
This table shows the independent variables and control variables that were used in the regression model, as well as the source and
description of each variable.
118 A. Batouli et al.significant correlations found would not simply be
due to a higher prevalence of deadlier cancer types
in certain countries.
3. Results
In general, cancer MIR was higher in middle/low-in-
come countries (Table 2). This difference in cancer
MIR persisted from region to region (Table 3), and
remained significant when controlling for HIV rate,
percent of population that was rural, per capita
ethanol consumption, smoking rates and obesity
rates. As expected, THE was greater in higher in-
come countries (Table 3). However, differences
in measures of healthcare infrastructure (TEBD)
and physician density were variable across world
regions, with relatively high physician density in
Western Asia (241 per 100,000) compared with
North America (150 per 100,000) and Eastern Asia
(159 per 100,000). High-income countries inWestern Europe, North America, and Oceania had
much higher TEBD (6.0, 5.9, and 5.8 per 100,000
population, respectively) than other regions and in-
come groups (0.8–3.4 per 100,000 population for
all others).
Within high-income countries, Eastern Europe
had the highest cancer MIR at 0.55 while Oceania
and Western Europe had the lowest at 0.39–0.40.
(p = 0.006) (Table 3). Within middle/low-income
countries, Western Asia had the highest cancer
MIR at 0.73, and the Americas had the lowest mor-
talities (0.59–0.62). In middle/low-income coun-
tries, MIR ranged from a low of 0.56 in Costa Rica
to a high of 0.78 in Armenia with a median of 0.64
in Guatemala (Table 2, Fig. 1). In high-income coun-
tries MIR ranged from a low of 0.38 in Australia to a
high of 0.73 in Greece with a median of 0.50 in Swe-
den. The United States and Luxembourg, the two
largest healthcare spenders globally, were tied for
the second lowest cancer MIR at 0.39 overall MIR.
Table 2 Ranking of all countries by cancer mortality-to-incidence rate ratio (MIR).
Rank Country MIR Rank Country MIR Rank Country MIR
1 Australia 0.3800 30 Costa Rica 0.5554 59 Guatemala 0.6441
2 Luxembourg 0.3861 31 Suriname 0.5558 60 Hungary 0.6461
3 United States 0.3937 32 Japan 0.5564 61 El Salvador 0.6495
4 New Zealand 0.4055 33 Portugal 0.5631 62 Belize 0.6507
5 Ireland 0.4061 34 Brunei 0.5669 63 Moldova 0.6525
6 Israel 0.4079 35 Venezuela 0.5751 64 Trinidad and Tobego 0.6527
7 Republic of Korea 0.4087 36 Argentina 0.5775 65 Albania 0.6569
8 Iceland 0.4248 37 Bahamas 0.5797 66 Belarus 0.6582
9 Finland 0.4278 38 Colombia 0.5814 67 Ecuador 0.6588
10 Norway 0.4297 39 Bulgaria 0.5841 68 Poland 0.6591
11 Canada 0.4364 40 Slovenia 0.5862 69 Romania 0.6612
12 France 0.4378 41 Lithuania 0.5923 70 Russian Fed 0.6638
13 Kuwait 0.4419 42 Brazil 0.5925 71 Mauritius 0.6657
14 Germany 0.4422 43 Uruguay 0.5931 72 Cuba 0.6734
15 Switzerland 0.4500 44 Nicaragua 0.5985 73 South Africa 0.6893
16 Belgium 0.4682 45 Paraguay 0.6009 74 China 0.6926
17 Singapore 0.4724 46 Barbados 0.6014 75 Turkmenistan 0.6993
18 Cyprus 0.4725 47 FYR Macedonia 0.6024 76 Kyrgyzstan 0.7021
19 Italy 0.4871 48 Croatia 0.6042 77 Uzbekistan 0.7040
20 Denmark 0.4889 49 Dominican Republic 0.6088 78 Serbia 0.7130
21 Sweden 0.4967 50 Mexico 0.6094 79 Georgia 0.7137
22 The Netherlands 0.4974 51 Ukraine 0.6114 80 Mongolia 0.7276
23 Czech Republic 0.5095 52 Chile 0.6139 81 Tajikistan 0.7287
24 United Kingdom 0.5142 53 Thailand 0.6253 82 Greece 0.7341
25 Chinese Taipei 0.5265 54 Philippines 0.6255 83 Kazakhstan 0.7400
26 Spain 0.5294 55 Latvia 0.6262 84 Azerbaijan 0.7720
27 Malta 0.5464 56 Peru 0.6318 85 Armenia 0.7817
28 Austria 0.5526 57 Estonia 0.6409
29 Slovakia 0.5546 58 Panama 0.6440
This table shows all countries included in this study, ranked by overall cancer MIR (calculated by deaths caused by cancer divided by
cancer incidence). Countries shown in green are high-income (GDP > $15,000) and those in red are middle/low-income
(GDP < $15,000). Western Europe, Oceania and North America have the lowest MIRs. In middle/low-income countries, Central and
South America have lower MIRs than much of Eastern Europe and Asia. Many of the highest MIRs are found in former or currently
communist countries in Eastern Europe and Western Asia.
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tries, controlling for HIV rate, percent of
population that was rural, per capita ethanol con-
sumption, smoking rates and obesity rates revealed
significant relationships between overall cancer
MIR and both overall financial resources and as-
pects of healthcare system infrastructure, but not
the WHO score (Table 4). Specifically, total health
expenditure (p < 0.001), GDP (p = 0.004), and total
external beam radiotherapy devices per capita
(p = 0.027) correlated with MIR, while WHO and
physician density did not. GNI, which showed an al-
most perfect correlation with GDP, also correlated
significantly with MIR (p = 0.033). The overall
R-squared for the model of best fit, which included
overall health expenditure, was 0.61.
In middle/low-income countries, when control-
ling for HIV rate, percent of population that wasrural, per capita ethanol consumption, smoking
rates and obesity rates, only the WHO score corre-
lated with the decreased overall cancer MIR
(p = 0.022) (Table 4). Physician density, one of sev-
eral measures of healthcare infrastructure, was
paradoxically associated with increasing MIR, with
an increase of 39 physicians per 100,000 corre-
sponding to a 0.01 increase in overall cancer MIR.
No other variables showed a significant association
with MIR in these countries. The overall R-squared
for the model for middle/low-income countries
was 0.69.
Twelve specific cancer types showed similarly
significant correlations in MIR (p < 0.05) as overall
cancer, including colorectal, breast, cervix, liver,
CNS, kidney, stomach, testis, liver, thyroid, naso-
pharynx, and head and neck cancer (data not
shown).
Table 3 Summary statistics by region for high- and middle/low-income countries.
Category Variable Region
High-income
Countries
(Per capita GDP > $15,000)
Eastern Europe Western Europe North America Eastern Asia Western Asia Oceania Overall
Countries 12 18 5 5 2 2 44
MIR 0.55 0.4 0.5 0.49 0.49 0.39 0.47
Financial
resources
GDP $21,043 $38,612 $31,212 $38,197 $42,393 $32,569 $32,418
THE $1,174 $4,451 $2,989 $1,552 $1,397 $3,388 $2,824
Healthcare
infrastructure
TEBD 3.4 6 5.9 2 2.5 5.8 4.7
Physician Density 322 347 150 159 274 230 284
Middle/Low-income
Countries
(Per capita GDP < $15,000)
Eastern Europe North America Central America South America Eastern Asia Western Asia Africa Overall
Countries 11 1 6 12 4 6 1 41
MIR 0.65 0.61 0.62 0.59 0.68 0.73 0.7 0.64
Financial
resources
GDP $8,951 $12,447 $7,340 $9,397 $4,893 $5,616 $10,632 $7,543
THE $387 $564 $257 $406 $93 $126 $497 $269
Healthcare
infrastructure
TEBD 1.6 1 0.8 1.7 0.8 1.1 1.2 1.2
Physician density 210 198 106 202 139 241 77 215
This table shows the mean for each variable used in the regression model (excluding controls) by region and income category. High-income countries had a GDP > $15,000 while middle/
low-income countries were below $15,000. All variables varied widely by region and income category. (MIR = Overall cancer mortality-to-incidence rate ratio, GDP = Gross Domestic
Product per capita, THE = total health expenditure per capita, TEBD = Total external beam radiation devices per 100,000 population, Physician Density = Physicians per 100,000
population)
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Fig. 1 Map of countries by cancer MIR. This figure shows a color-coded map of age-adjusted MIR for all cancers.
Lighter colors correspond with lower MIR. As seen numerically in Table 2, Western Europe, Oceania and North America
have the lowest MIR. In middle/low-income countries, Central and South America have lower MIR rates than much of
Eastern Europe and Asia.
Table 4 Significant correlates of overall cancer mortality-to-incidence rate ratio (MIR) in middle/low- and high-income
countries.
Category Variable High-income Middle/low-income
0.01 # MIR 95% Confidence
Interval
p-value 0.01 # MIR 95% Confidence
Interval
p-value
Organization WHO score – – – 0.07 (3.8%, 44.4%) 0.022
Financial
Resources
GDP $3040 ($1828, $9091) 0.004 – – –
THE $379 ($248, $800) <0.001 – – –
Healthcare
Infrastructure
TEBD 0.59 (0.31, 4.93) 0.027 – – –
Physician Density – – – 39 (74, 26) <0.001
This table shows significant correlates of overall cancer MIR, as well as the increase in each variable needed to cause a 0.01
decrease in cancer MIR. For example, in high-income countries, a $3040 increase in GDP per capita is associated with a 0.01
decrease in overall cancer MIR (p = 0.004). While GDP, THE, and TEBD all showed significant inverse correlations with MIR in high-
income countries, THE showed the strongest correlation (highest R and lowest p-value). In middle/low-income countries, only the
WHO score correlated with decreased overall cancer MIR, while physician density paradoxically correlated with increased MIR.
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Though cancer MIR varied widely throughout the
world, in general, countries with a lower income
had higher cancer MIR. The difference in cancer
MIR between the highest income and lowest in-
come countries was dramatic. Furthermore, quan-
tifiable measures of overall monetary resources,
healthcare infrastructure, and healthcare system
organization appeared to impact cancer MIR in dif-
ferent ways in high-income vs. middle- and low-in-
come countries. Whereas financial resources andinfrastructure showed significant correlations with
overall cancer MIR in high-income countries, can-
cer MIR in middle/low-income countries was most
correlated to the WHO health system score.
Although there was a continuum of low-, middle-,
and high-income countries as defined by the World
Bank, this study was limited in its analysis of coun-
tries by stratification into two equal groups to al-
low for adequate sample sizes for significant
differences and correlations to be noted. Addition-
ally, there is a limited application of the results of
this study to the roughly 30 countries designated by
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countries in this study that belonged to this group
were Kyrgyzstan and Tajikistan.
For high-income countries, GDP, THE, and ac-
cess to radiation oncology were all significantly
associated with reduced MIR–THE showing the
strongest correlation. Thus, in countries with a
GDP > $15,000, healthcare spending appeared to
make a difference in cancer MIR. This was likely a
result not only of increased spending on cancer
treatment, but also on early detection through rel-
atively expensive widespread screening tech-
niques, such as mammography and colonoscopy.
In contrast, for middle/low-income countries, the
WHO overall healthcare system score was the only
variable strongly associated with improvement in
overall cancer MIR. This finding suggested that for
middle/low-income countries, increased health-
care expenditure may not have significantly im-
proved national cancer MIR in the presence of an
unequal distribution of healthcare resources. Addi-
tionally, there may have been a minimum threshold
of national income and spending beyond which an
increase in healthcare expenditure and infrastruc-
ture was associated with improved cancer MIR.
As noted previously, a large part of the WHO
healthcare system score was based on the equality
of health resources distribution. In the setting of
low national resources, equality and spreading
the limited healthcare expenditure available to en-
sure widespread access to the most basic cancer
screening and treatment was imperative to effec-
tive healthcare. In high-income countries, due to
the high cost of the most modern cancer treatment
[11], it may have been difficult to provide the most
effective treatments to every patient if those
treatments are resource-intensive. More equitable
high-income nationalized systems may have chosen
not to offer the most advanced treatments in order
to limit costs and focus more on less expensive dis-
eases. Thus, high-income countries which offered
the most advanced but expensive treatments to
only a portion of the population may have had an
edge in overall cure rates compared with their
more equitable high-income counterparts.
Limiting this study was the lack of data on the
lowest income countries, particularly those in Afri-
ca. African countries had a per capita GDP on an
average less than half of the next most resource-
limited continent: Asia. However, the burden of
cancer was devastating in Africa. For example,
the risk of dying from cancer among African women
was double that of developed countries [12]. Thus,
future research analyzing correlates of cancer MIR
in the lowest income countries is necessary oncemore sufficient data are available. Another limita-
tion was the potential impact of unmeasured
variables on cancer outcomes. For example,
expenditure on social welfare has been shown to
be an independent correlate of general health out-
comes in developed countries, even surpassing
healthcare expenditure itself in some countries
[13]. Finally, the accuracy of a countrys cancer
statistics has itself been shown to be a measure
of health system organization. Lower income coun-
tries with the least access to health care likely had
the greatest underestimation of cancer death, as
many people died without seeing a physician. This
may also have explained the underlying reason for
the paradoxical finding of increased cancer MIR
with increased physician density among middle/
low-income countries: More physicians may have
meant more diagnosing and recording of cancer
death. Additionally, the number of physicians
trained to diagnose and treat cancer may not have
correlated with the total number of physicians,
especially in countries focused primarily on pro-
ducing large quantities of primary care physicians.
Finally, it is important to note that higher physician
density was found in more socialist/communist in-
clined countries with more centrally organized
healthcare systems. For example, among middle/
low income countries, Cuba, Belarus, Georgia,
Lithuania, and Kazakhstan had the five highest
number of physicians per capita. Every single one
of these countries is currently, or has been in re-
cent history under communist influence. Ideologi-
cally, it would make sense that such countries
would centrally organize their healthcare systems
to use their limited resources to produce higher
numbers of primary care physicians and spend less
resources on screening for and treating expensive
diseases such as cancer.
Another limitation of this analysis was the use of
GDP, rather than per capita Gross National Income
(GNI). Though GDP is a commonly quoted indicator
of overall economic development, GNI is used by
economic entities such as the World Bank to clas-
sify countries by income. However, though GDP
does not take into consideration the national debt
or the extent to which natural resources are sold to
external entities, GDP and GNI tend to track to-
gether; these findings were unchanged when using
GNI as with GDP. Thus, while mention was made
of the GNI results, the original formulation of
GDP was used in reporting and discussing the
majority of this study.
Another limitation of this analysis was the po-
tential bias introduced by measuring the MIR for
countries with differences in cancer presentation.
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ity in the distribution of cancer types across
nations, particularly between developed and
developing countries [14]. Whereas prostate can-
cer was the most common cancer in men in the Uni-
ted States [15], lung cancer was the most common
in China [16]. As lung cancer was more deadly than
prostate cancer, this difference in cancer preva-
lence would potentially raise the MIR of China rel-
ative to the United States. Nonetheless, this did
not necessarily invalidate the analysis, as the pre-
vention of potentially deadlier cancers such as lung
cancer and other cancers responsive to public
health campaigns was certainly something that
the increased health expenditure could address.
The aggregate approach to cancer MIR was impor-
tant, as it allowed for a global assessment, inclu-
sive of all cancer types. Additionally, 12 specific
cancer types showed similar significant correla-
tions (p < 0.05) as overall cancer MIR. Future work
is needed to explore the relative impact of national
income and healthcare resources on specific cancer
types.
The other bias introduced by differences in can-
cer presentation was due to the sensitivity of MIR
to lead time bias. If countries that had greater in-
come and healthcare expenditure were detecting
cancers earlier in the treatment course, this would
potentially improve a countrys measured MIR by
increasing the amount of time from diagnosis to
death, despite a lack of actual improvement in a
countrys cancer MIR. The analysis of middle/low-
income countries separated from high-income
countries hopefully reduces this bias, by grouping
countries with others that theoretically had similar
levels of early cancer detection. Although MIR was
not without its potential biases, the alternative
would have required financially and logistically
challenging, worldwide cohort survival studies.
Nonetheless, these biases were a significant limita-
tion that needed to be acknowledged.
As this was a retrospective correlational study,
no conclusions could be made regarding causality.
Additional research is required to parse out individ-
ual effects of each variable and to find additional
factors that may be associated with cancer MIR.
This could help better inform future policy deci-
sions on a national and global scale. Further re-
search is also necessary to explore whether a
health expenditure threshold exists for middle/
low-income countries, and what values of GDP,
overall healthcare expenditure, and total external
beam devices may be cutoff points after which sig-
nificant improvement in cancer outcomes is seen.
More detailed analyses of outlier countries arenecessary in order to investigate how certain coun-
tries with lower levels of resources outperform
their richer counterparts. Finally, further research
is necessary to reconfirm and understand the key
result of this analysis: that healthcare system
effectiveness and organization as measured by
the WHO healthcare score was associated with im-
proved cancer outcomes in middle/low-income
countries while absolute resource and infrastruc-
ture level played a more important role in high-in-
come countries. Despite the debate within the
scientific and political community regarding the
methodology and utility of the rankings [17], little
research has been done to evaluate the effective-
ness of the rankings in predicting national health
outcomes.
5. Conclusions
In general, cancer MIR was greater in lower income
countries compared to higher income countries.
While overall financial resources and healthcare
infrastructure were strongly associated with cancer
MIR in high-income countries, the World Health
Organizations healthcare system score was the
only correlate of MIR in middle/low-income coun-
tries. This may suggest a greater importance of
healthcare system structure and equality in lower
income countries vs. absolute levels of resources
in higher income countries.
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identifiers in this paper.Appendix A. WHO healthcare system
score explanation
The year 2000 WHO ranking of healthcare systems,
124 A. Batouli et al.which scored and ranked the USA, the nation
spending the highest amount of money per capita
on healthcare at the time, 37th, was a quantifiable
variable that attempted to quantify nations overall
levels of health and healthcare system perfor-
mance. The score was a complex index based on
an aggregate of several variables: the systems
responsiveness to patients, the fairness of financial
distribution, the overall national level of health,
and the distribution of health. The responsiveness
measure included two major components: respect
for persons and client orientation. One example
of a measured outcome in this category was the
ability of patients to obtain the care and treat-
ments they required in a timely fashion. Fairness
of financial distribution measured the relative
out-of-pocket amount paid by the rich and poor.
According to this definition, fairer systems were
ones in which poorer patients and citizens paid a
smaller portion of healthcare costs than did
wealthier ones, either through taxes or other
means. The overall national level of health was
counted as the average disability adjusted life
expectancy (DALE) of the nation, which is a mea-
sure of the number of healthy years lived by each
citizen of the country. The distribution of health
was concerned with the variance of DALE around
the mean, with countries with more narrow distri-
butions receiving higher scores.
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